This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutConjugate TechnologyPneumococcal DiseaseDosing & AdministrationDosing & AdministrationDosing, Administration & StoragePrevious pneumococcal VxClinical Trial ProgrammeClinical Evidence & SafetyClinical Trial programmeSafety ProfilePrivate Vaccination Service Private Vaccination ServiceIdentifying Those at Increased Risk of Pneumococcal PneumoniaSupport & ResourcesSupport & ResourcesVideosMaterials

Prescribing Information for APEXXNAR®▼ (pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)) can be found here and for Prevenar 13® (pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) can be found here. Adverse event reporting information can be found at the bottom of the page
APEXXNAR
​​​​​​APEXXNAR® is a 20-valent pneumococcal conjugate vaccine for adults that helps protect against the 20 Streptococcus pneumoniae serotypes included in the vaccine1

APEXXNAR is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.1

  
  • APEXXNAR adds 7 serotypes to Prevenar 13 to deliver the most serotypes in a pneumococcal conjugate vaccine.1,2
 
  • APEXXNAR may help to protect against more disease than any other pneumococcal conjugate; studies have demonstrated the immunogenicity and safety profile of APEXXNAR in both vaccine-naïve and previously vaccinated adults.1,2 
 
  • APEXXNAR will only protect against Streptococcus pneumoniae serotypes included in the vaccine, and will not protect against other microorganisms that cause invasive disease or pneumonia.1

APEXXNAR helps prevent invasive disease and pneumonia caused by 20 pneumococcal serotypes in individuals 18 years of age and older1


† Data extracted from routine national IPD surveillance data from England and Wales from 2000 to 2017.4 For adults aged 65+ years the number of IPD cases occurring in 2016/17 are described for 27 individual serotypes, including all those in PCV13 and PCV20.3,4

PCV13: pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
PCV20: pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)

 About APEXXNAR

A short guide to conjugate vaccine technology
 

How it works →    Loading

 Clinical Trial Programme

The safety profile and immunogenicity of APEXXNAR was evaluated in 4,552 adults in 6 trials1

 See the data →Loading

 Key Information on APEXXNAR

Key information about dosing, administration and storage of APEXXNAR1

 Get the facts →Loading

References:

  1. APEXXNAR GB (Pneumococcal polysaccharide conjugate vaccine). Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/13461. Accessed August 2022.
  2. Prevenar 13 GB (Pneumococcal polysaccharide conjugate vaccine). Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/22689. Accessed August 2022.
  3. Vyse A, et al. Vaccine. The proportion of contemporary invasive pneumococcal disease and pneumococcal pneumonia in UK adults reflected by serotypes included in the 13-valent pneumococcal conjugate vaccine and next generation higher valency pneumococcal conjugate vaccines in development. Vaccine. 2020;38(51):8068-8070. doi: 10.1016/j.vaccine.2020.10.090. Epub 2020 Nov 1.
  4. Ladhani SN et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis 2018;18(4):441–51.
PP-PNR-GBR-0035. August 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​